Fennec Pharmaceuticals/$FENC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
- Ticker
- $FENC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 35
- Headquarters
- Research Triangle Park, United States
- Website
- www.fennecpharma.com
FENC Metrics
BasicAdvanced
$344M
-
-$0.10
1.07
-
Price and volume
Market cap
$344M
Beta
1.07
52-week high
$13.25
52-week low
$5.65
Average daily volume
133K
Financial strength
Current ratio
5.85
Quick ratio
5.205
Interest coverage (TTM)
-1.19%
Profitability
EBITDA (TTM)
-1.021
Gross margin (TTM)
93.73%
Net profit margin (TTM)
-5.49%
Operating margin (TTM)
-1.90%
Effective tax rate (TTM)
-4.77%
Revenue per employee (TTM)
$1,690,000
Management effectiveness
Return on assets (TTM)
-1.16%
Return on equity (TTM)
-18.58%
Valuation
Price to revenue (TTM)
5.312
Price to book
8.1
Price to tangible book (TTM)
8.1
Price to free cash flow (TTM)
-154.194
Free cash flow yield (TTM)
-0.65%
Free cash flow per share (TTM)
-0.064
Growth
Revenue change (TTM)
77.83%
Earnings per share change (TTM)
-77.26%
3-year revenue growth (CAGR)
108.46%
3-year earnings per share growth (CAGR)
-53.35%
10-year earnings per share growth (CAGR)
-4.55%
What the Analysts think about FENC
Analyst ratings (Buy, Hold, Sell) for Fennec Pharmaceuticals stock.
Analyst projections of the future price of Fennec Pharmaceuticals stock.
Bulls say / Bears say
PEDMARK sales rose 78% year on year to $17.1 million in the second quarter, with adjusted EBITDA of $2.8 million and cash of $41.2 million. That suggests the growing commercial business is beginning to generate profits and fund itself. (Fennec Pharmaceuticals Inc.)
An investigator-led Phase 2 study in Japan met its primary endpoint, showing significant hearing protection without evidence of interference with cisplatin’s anti-cancer activity. This supports the case for seeking Japanese registration and a commercial partner. (U.S. Securities and Exchange Commission)
International licensing offers a route to growth beyond US sales: management said Norgine planned to launch PEDMARQSI in ten markets during the second half of 2026. Successful launches could bring Fennec royalties and milestone payments without requiring it to build its own sales operation in those territories. (StockAnalysis, U.S. Securities and Exchange Commission)
Commercial expansion is costly: second-quarter selling and marketing expense more than doubled year on year to $10.7 million, against $17.1 million of PEDMARK sales. If sales growth slows, those higher costs could weigh on margins. (Fennec Pharmaceuticals Inc.)
Fennec depends on a single product, and PEDMARK’s approved use is limited to children with localised, non-metastatic solid tumours. Broader adult and metastatic uses remain exploratory and would need further clinical evidence and regulatory approval, limiting how quickly the company can expand its market. (U.S. Securities and Exchange Commission)
Cipla could enter the US market with a generic version from 1 September 2033, or earlier in specified circumstances. Generic competition would put pressure on Fennec’s key revenue source, and its filings also warn that patent protection could be challenged or circumvented. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
FENC Financial Performance
Revenues and expenses
FENC Earnings Performance
Company profitability
Upcoming events
No upcoming events
FENC News
AllArticlesVideos
Funds containing FENC
Fund name | Fund size | $FENC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.